Φορτώνει......
Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
AIMS: There is a controversy as to the relative efficacy of (177)Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether (177)L...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Eur J Nucl Med Mol Imaging |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Berlin Heidelberg
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5787223/ https://ncbi.nlm.nih.gov/pubmed/29247284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-017-3895-x |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|